|
Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic …
PR Newswire (press release) Statistically, regadenoson was found to be not significantly different from placebo in causing a >15% decrease in FEV1 in patients with asthma (p = 0.1451) … |
View full post on asthma – Google News